Want to join the conversation?
$IPXL said that it has received U.S. FDA's final approval for its generic version of Avodart (Dutasteride) capsules 0.5 mg on Nov. 20, 2015, which is used to treat benign prostatic hyperplasia in men with enlarged prostate. According to IMS Health, U.S. brand & generic sales of Dutasteride were about $457MM for 12 months ended Sept. 2015.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?